Future pharmas may be increasingly specialized; Western vanity projected to drive cosmeceuticals;

> Expect pharma manufacturers may become increasingly specialized as they adopt strategies based on particular diseases related to specific systems in the human body or targeted populations. Analysis

> An aging population bent on maintaining its youth is expected to push U.S. demand for cosmeceuticals to 5.8% a year to reach $8.5 billion in 2015, projects Freedonia Group. Report

> The biggest challenge facing India in the food and drug industries is supply chain infrastructure, which "really needs to be overhauled for foreign players, contract manufacturing and cold-chain storage." Article

> Drug-delivery specialist OctoPlus wants you, if you're a specialty manufacturer of generics interested in controlled-release technology. Story

> BioAlliance Pharma will produce clinical batches of the orphan-designated Livatag (doxorubicin Transdrug), an injectable cytotoxin in nanoparticle form for a Phase III trial in liver cancer. Story

> Cadila Pharmaceuticals in Ethiopia anticipates international GMP certification from the Pharmaceutical Inspection Cooperation Scheme. Item

> Baxter in Europe has been named a "Great Place to Work" by the GPTW Institute. News

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.